A current understanding of vascular calcification in CKD

American Journal of Physiology - Renal Physiology

Volumn 307, Issue 8, 2014, Pages F891-F900

  Paloian, Neil J ^a   Giachelli, Cecilia M ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b University of Washington   (United States)

Author keywords

Calciprotein particles; Chronic kidney disease; MicroRNA; Vascular calcification; Vesicles

Indexed keywords

BIOLOGICAL MARKER; CALCIPROTEIN; CALCIUM; ELASTIN; MICRORNA; PHOSPHORUS; UNCLASSIFIED DRUG;

BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; DISEASE COURSE; END STAGE RENAL DISEASE; HUMAN; MORBIDITY; NONHUMAN; OSSIFICATION; PATHOLOGY; PROTEIN DEGRADATION; REVIEW; RISK FACTOR; CHRONIC KIDNEY FAILURE; CYTOLOGY; METABOLISM; PATHOPHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

CALCIUM; DISEASE PROGRESSION; ELASTIN; HUMANS; KIDNEY FAILURE, CHRONIC; MUSCLE, SMOOTH, VASCULAR; PHOSPHORUS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; VASCULAR CALCIFICATION;

EID: 84908061325     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00163.2014     Document Type: Review

References (127)

1. Aikawa E, Aikawa M, Libby P, Figueiredo JL, Rusanescu G, Iwamoto Y, Fukuda D, Kohler RH, Shi GP, Jaffer FA, Weissleder R. Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation 119: 1785-1794, 2009.
2. Amabile N, Guerin AP, Leroyer A, Mallat Z, Nguyen C, Boddaert J, London GM, Tedgui A, Boulanger CM. Circulating endothelial mi-croparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 16: 3381-3388, 2005.
3. Amabile N, Guerin AP, Tedgui A, Boulanger CM, London GM. Predictive value of circulating endothelial microparticles for cardiovascular mortality in end-stage renal failure: a pilot study. Nephrol Dial Transplant 27: 1873-1880, 2012.
4. Anderson HC. Electron microscopic studies of induced cartilage development and calcification. J Cell Biol 35: 81-101, 1967.
5. Asmus HG, Braun J, Krause R, Brunkhorst R, Holzer H, Schulz W, Neumayer HH, Raggi P, Bommer J. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 20: 1653-1661, 2005.
6. Balderman JAF, Lee HY, Mahoney CE, Handy DE, White K, Annis S, Lebeche D, Hajjar RJ, Loscalzo J, Leopold JA. Bone morphoge-netic protein-2 decreases microRNA-30b and microRNA-30c to promote vascular smooth muscle cell calcification. J Am Heart Assoc 1: e003905, 2012.
7. Barreto DV, Lenglet A, Liabeuf S, Kretschmer A, Barreto FC, Nollet A, Slama M, Choukroun G, Brazier M, Massy Z. Prognostic implication of plasma osteopontin levels in patients with chronic kidney disease. Nephron Clin Pract 117: c363-c372, 2011.
8. Chang CP, Zhao J, Wiedmer T, Sims PJ. Contribution of platelet microparticle formation and granule secretion to the transmembrane migration of phosphatidylserine. J Biol Chem 268: 7171-7178, 1993.
9. Chen NX, Kiattisunthorn K, O'Neill KD, Chen X, Moorthi RN, Gattone VH, Allen MR, Moe SM. Decreased microRNA is involved in the vascular remodeling abnormalities in chronic kidney disease (CKD). PLoS ONE 8: e64558, 2013.
10. Chen NX, Kircelli F, O'Neill KD, Chen X, Moe SM. Verapamil inhibits calcification and matrix vesicle activity of bovine vascular smooth muscle cells. Kidney Int 77: 436-442, 2010.
11. Chen NX, O'Neill KD, Chen X, Duan D, Wang E, Sturek MS, Edwards JM, Moe SM. Fetuin-A uptake in bovine vascular smooth muscle cells is calcium dependent and mediated by annexins. Am J Physiol Renal Physiol 292: F599-F606, 2007.
12. Chen NX, O'Neill KD, Chen X, Moe SM. Annexin-mediated matrix vesicle calcification in vascular smooth muscle cells. J Bone Miner Res 23: 1798-1805, 2008.
13. Chironi G, Simon A, Hugel B, Del Pino M, Gariepy J, Freyssinet JM, Tedgui A. Circulating leukocyte-derived microparticles predict subclin-ical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol 26: 2775-2780, 2006.
14. Cozzolino M, Mazzaferro S, Pugliese F, Brancaccio D. Vascular calcification and uremia: what do we know? Am J Nephrol 28: 339-346, 2008.
15. Crouthamel MH, Lau WL, Leaf EM, Chavkin NW, Wallingford MC, Peterson DF, Li X, Liu Y, Chin MT, Levi M, Giachelli CM. Sodium-dependent phosphate cotransporters and phosphate-induced calcification of vascular smooth muscle cells: redundant roles for PiT-1 and PiT-2. Arterioscler Thromb Vasc Biol 33: 2625-2632, 2013.
16. Cui RR, Li SJ, Liu LJ, Yi L, Liang QH, Zhu X, Liu GY, Liu Y, Wu SS, Liao XB, Yuan LQ, Mao DA, Liao EY. MicroRNA-204 regulates vascular smooth muscle cell calcification in vitro and in vivo. Cardiovasc Res 96: 320-329, 2012.
17. Dai XY, Zhao MM, Cai Y, Guan QC, Zhao Y, Guan Y, Kong W, Zhu WG, Xu MJ, Wang X. Phosphate-induced autophagy counteracts vascular calcification by reducing matrix vesicle release. Kidney Int 83: 1042-1051, 2013.
18. Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Chouk-roun G, Drueke TB, Massy ZA. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 23: 2017-2025, 2012.
19. Deuell KA, Callegari A, Giachelli CM, Rosenfeld ME, Scatena M. RANKL enhances macrophage paracrine pro-calcific activity in high phosphate-treated smooth muscle cells: dependence on IL-6 and TNF-a. J Vasc Res 49: 510-521, 2012.
20. Du Y, Gao C, Liu Z, Wang L, Liu B, He F, Zhang T, Wang Y, Wang X, Xu M, Luo GZ, Zhu Y, Xu Q, Wang X, Kong W. Upregulation of a disintegrin and metalloproteinase with thrombospondin motifs-7 by miR-29 repression mediates vascular smooth muscle calcification. Arte-rioscler Thromb Vasc Biol 32: 2580-2588, 2012.
21. El-Abbadi M, Giachelli CM. Mechanisms of vascular calcification. Adv Chronic Kidney Dis 14: 54-66, 2007.
22. El-Shehaby AM, Zakaria A, El-Khatib M, Mostafa N. Association of fetuin-A and cardiac calcification and inflammation levels in hemodial-ysis patients. Scand J Clin Lab Invest 70: 575-582, 2010.
23. Fang Y, Ginsberg C, Sugatani T, Monier-Faugere MC, Malluche H, Hruska KA. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int 85: 142-150, 2014.
24. Farzaneh-Far A, Weissberg PL, Proudfoot D, Shanahan CM. Tran-scriptional regulation of matrix gla protein. Z Kardiol 90, Suppl 3: 38-42, 2001.
25. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188: 997-1001, 1998.
26. Gauthier-Bastien A, Ung RV, Lariviere R, Mac-Way F, Lebel M, Agharazii M. Vascular remodeling and media calcification increases arterial stiffness in chronic kidney disease. Clin Exp Hypertens 36: 173-180, 2014.
27. Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res 96: 717-722, 2005.
28. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 15: 2959-2964, 2004.
29. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 75: 890-897, 2009.
30. Glatz AC, Pawel BR, Hsu DT, Weinberg P, Chrisant MRK. Idiopathic infantile arterial calcification: two case reports, a review of the literature and a role for cardiac transplantation. Pediatr Transplant 10: 225-233, 2006.
31. Goettsch C, Rauner M, Pacyna N, Hempel U, Bornstein SR, Hof-bauer LC. miR-125b regulates calcification of vascular smooth muscle cells. Am J Pathol 179: 1594-600, 2011.
32. Goldsmith D, Ritz E, Covic A. Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int 66: 1315-1333, 2004.
33. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483, 2000.
34. Gui T, Zhou G, Sun Y, Shimokado A, Itoh S, Oikawa K, Muragaki Y. MicroRNAs that target Ca2+ transporters are involved in vascular smooth muscle cell calcification. Lab Invest 92: 1250-1259, 2012.
35. Hamano T, Matsui I, Mikami S, Tomida K, Fujii N, Imai E, Rakugi H, Isaka Y. Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol 21: 1998-2007, 2010.
36. Heiss A, DuChesne A, Denecke B, Grotzinger J, Yamamoto K, Renne T, Jahnen-Dechent W. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 278: 13333-13341, 2003.
37. Heiss A, Eckert T, Aretz A, Richtering W, van Dorp W, Schafer C, Jahnen-Dechent W. Hierarchical role of fetuin-A and acidic serum proteins in the formation and stabilization of calcium phosphate particles. J Biol Chem 283: 14815-14825, 2008.
38. Heiss A, Jahnen-Dechent W, Endo H, Schwahn D. Structural dynamics of a colloidal protein-mineral complex bestowing on calcium phosphate a high solubility in biological fluids. Biointerphases 2: 16-20, 2007.
39. Hergenreider E, Heydt S, Treguer K, Boettger T, Horrevoets AJG, Zeiher AM, Scheffer MP, Frangakis AS, Yin X, Mayr M, Braun T, Urbich C, Boon RA, Dimmeler S. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol 14: 249-256, 2012.
40. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Gladziwa U, Rensma PL, Bartelet K, Konings CJ, Hoeks AP, Floege J, Leunissen KM. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant 21: 1293-1299, 2006.
41. Herrmann M, Schafer C, Heiss A, Graber S, Kinkeldey A, Biischer A, Schmitt MMN, Bornemann J, Nimmerjahn F, Herrmann M, Helming L, Gordon S, Jahnen-Dechent W. Clearance of fetuin-A-containing calciprotein particles is mediated by scavenger receptor-A. Circ Res 111: 575-584, 2012.
42. Hosaka N, Mizobuchi M, Ogata H, Kumata C, Kondo F, Koiwa F, Kinugasa E, Akizawa T. Elastin degradation accelerates phosphate-induced mineralization of vascular smooth muscle cells. Calcif Tissue Int 85: 523-529, 2009.
43. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96: 3540-3545, 1999.
44. Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 19: 235-244, 2004.
45. Jansen RS, Kiiiiikosiiianoglii A, de Haas M, Sapthu S, Otero JA, Hegman IEM, Bergen AAB, Gorgels TGMF, Borst P, van de Wetering K. ABCC6 prevents ectopic mineralization seen in pseudoxan-thoma elasticum by inducing cellular nucleotide release. Proc Natl Acad Sci USA 110: 20206-20211, 2013
46. Jayachandran M, Litwiller RD, Owen WG, Heit JA, Behrenbeck T, Mulvagh SL, Araoz PA, Budoff MJ, Harman SM, Miller VM. Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol 295: H931-H938, 2008.
47. Jean G, Bresson E, Lorriaux C, Mayor B, Hurot JM, Deleaval P, Chazot C. Increased levels of serum parathyroid hormone and fibroblast growth factor-23 are the main factors associated with the progression of vascular calcification in long-hour hemodialysis patients. Nephron Clin Pract 120: c132-c138, 2012.
48. Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C. Peripheral vascular calcification in long-haemodi-alysis patients: associated factors and survival consequences. Nephrol Dial Transplant 24: 948-955, 2009.
49. Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res 100: 1579-1588, 2007.
50. Jung HH, Kim SW, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant 21: 1915-1920, 2006.
51. Kaartinen MT, Murshed M, Karsenty G, McKee MD. Osteopontin upregulation and polymerization by transglutaminase 2 in calcified arteries of Matrix Gla protein-deficient mice. J Histochem Cytochem 55: 375-386, 2007.
52. Kapustin AN, Davies JD, Reynolds JL, McNair R, Jones GT, Sidibe A, Schurgers LJ, Skepper JN, Proudfoot D, Mayr M, Shanahan CM. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res 109: e1-e12, 2011.
53. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL. Serum phosphate levels and mortality risk among people with chronic kidney disease. JAmSoc Nephrol 16: 520-528, 2005.
54. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 361: 827-833, 2003.
55. Lau WL, Festing MH, Giachelli CM. Phosphate and vascular calcification: emerging role of the sodium-dependent phosphate co-transporter PiT-1. Thromb Haemost 104: 464-470, 2010.
56. Lau WL, Pai A, Moe SM, Giachelli CM. Direct effects of phosphate on vascular cell function. Adv Chronic Kidney Dis 18: 105-112, 2011.
57. Leopold JA. Vascular calcification: an age-old problem of old age. Circulation 127: 2380-2382, 2013.
58. Leroyer AS, Isobe H, Leseche G, Castier Y, Wassef M, Mallat Z, Binder BR, Tedgui A, Boulanger CM. Cellular origins and thrombo-genic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol 49: 772-777, 2007.
59. Li X, Giachelli CM. Sodium-dependent phosphate cotransporters and vascular calcification. Curr Opin Nephrol Hypertens 16: 325-328, 2007.
60. Li X, Yang H., Giachelli CM. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 98: 905-912, 2006.
61. Liao XB, Zhang ZY, Yuan K, Liu Y, Feng X, Cui RR, Hu YR, Yuan ZS, Gu L, Li SJ, Mao DA, Lu Q, Zhou XM, de Jesus Perez VA, Yuan LQ. MiR-133a modulates osteogenic differentiation of vascular smooth muscle cells. Endocrinology 154: 3344-3352, 2013.
62. Lomashvili KA, Khawandi W, O'Neill WC. Reduced plasma pyro-phosphate levels in hemodialysis patients. J Am Soc Nephrol 16: 24952500, 2005.
63. Lomashvili KA, Narisawa S, Millan JL, O'Neill WC. Vascular calcification is dependent on plasma levels of pyrophosphate. Kidney Int 85: 1351-1356, 2014.
64. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18: 1731-1740, 2003.
65. London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol 14: S305-S309, 2003.
66. Mackenzie NCW, Staines KA, Zhu D, Genever P, Macrae VE. miRNA-221 and miRNA-222 synergistically function to promote vascular calcification. Cell Biochem Funct 32: 209-216, 2014.
67. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 99: 348-353, 1999.
68. Matsui I, Hamano T, Mikami S, Fujii N, Takabatake Y, Nagasawa Y, Kawada N, Ito T, Rakugi H, Imai E, Isaka Y. Fully phosphorylated fetuin-A forms a mineral complex in the serum of rats with adenine-induced renal failure. Kidney Int 75: 915-928, 2009.
69. McCabe KM, Booth SL, Fu X, Shobeiri N, Pang JJ, Adams MA, Holden RM. Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int 83: 835-844, 2013.
70. Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J, Gupta A, Norris K, Ketteler M, Adler S. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int 67: 1070-1077, 2005.
71. Mesquita M, Demulder A, Damry N, Melot C, Wittersheim E, Willems D, Dratwa M, Bergmann P. Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease. Clin Chem Lab Med 47: 339-346, 2009.
72. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 20: 1453-1464, 2009.
73. Moe SM, Reslerova M, Ketteler M, O'neill K, Duan D, Koczman J, Westenfeld R, Jahnen-Dechent W, Chen NX. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 67: 2295-2304, 2005.
74. Neves KR, Graciolli FG, dos Reis LM, Graciolli RG, Neves CL, Magalhaes AO, Custodio MR, Batista DG, Jorgetti V, Moyses RMA. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 71: 1262-1270, 2007.
75. New SEP, Aikawa E. Role of extracellular vesicles in de novo mineralization: an additional novel mechanism of cardiovascular calcification. Arterioscler Thromb Vasc Biol 33: 1753-1758, 2013.
76. New SEP, Goettsch C, Aikawa M, Marchini JF, Shibasaki M, Yabusaki K, Libby P, Shanahan CM, Croce K, Aikawa E. Macro-phage-derived matrix vesicles: an alternative novel mechanism for mi-crocalcification in atherosclerotic plaques. Circ Res 113: 72-77, 2013.
77. Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, Maquelin KN, Roozendaal KJ, Jansen PG, ten Have K, Eijsman L, Hack CE, Sturk A. Cell-derived microparticles generated in patients during cardiopulmo-nary bypass are highly procoagulant. Circulation 96: 3534-3541, 1997.
78. Pai A, Leaf EM, El-Abbadi M, Giachelli CM. Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease. Am J Pathol 178: 764-773, 2011.
79. Pai AS, Giachelli CM. Matrix remodeling in vascular calcification associated with chronic kidney disease. J Am Soc Nephrol 21: 16371640, 2010.
80. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, Lopez-Ongil S, Coll B, Fernandez E, Valdivielso JM. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 104: 1041-1048, 2009.
81. Pasch A, Farese S, Graber S, Wald J, Richtering W, Floege J, Jahnen-Dechent W. Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol 23: 1744-1752, 2012.
82. Persy V, D'Haese P. Vascular calcification and bone disease: the calcification paradox. Trends Mol Med 15: 405-416, 2009.
83. Price PA, Lim JE. The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. J Biol Chem 278: 22144-22152, 2003.
84. Price PA, Nguyen TMT, Williamson MK. Biochemical characterization of the serum fetuin-mineral complex. J Biol Chem 278: 22153-22160, 2003.
85. Price PA, Thomas GR, Pardini AW, Figueira WF, Caputo JM, Williamson MK. Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix gamma-carboxyglutamic acid protein in the serum of etidronate-treated rats. J Biol Chem 277: 3926-3934, 2002.
86. Price PA, Urist MR, Otawara Y. Matrix Gla protein, a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Biochem Biophys Res Commun 117: 765-771, 1983.
87. Price PA, Williamson MK, Nguyen TMT, Than TN. Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat. J Biol Chem 279: 1594-1600, 2004.
88. Proudfoot D, Shanahan CM. Molecular mechanisms mediating vascular calcification: role of matrix Gla protein. Nephrology (Carlton) 11: 455-461, 2006.
89. Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, Weissberg PL. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 87: 1055-1062, 2000.
90. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26: 1327-1339, 2011.
91. Rangrez AY, M'Baya-Moutoula E, Metzinger-Le Meuth V, Henaut L, Djelouat MS, Benchitrit J, Massy Z., Metzinger L. Inorganic phosphate accelerates the migration of vascular smooth muscle cells: evidence for the involvement of miR-223. PLoS ONE 7: e47807, 2012.
92. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 15: 2857-2867, 2004.
93. Reynolds JL, Skepper JN, McNair R, Kasama T, Gupta K, Weiss-berg PL, Jahnen-Dechent W, Shanahan CM. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 16: 2920-2930, 2005.
94. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 340: 115-126, 1999.
95. Roy ME, Nishimoto SK. Matrix Gla protein binding to hydroxyapatite is dependent on the ionic environment: calcium enhances binding affinity but phosphate and magnesium decrease affinity. Bone 31: 296-302, 2002.
96. Russo D, Corrao S, Battaglia Y, Andreucci M, Caiazza A, Carlom-agno A, Lamberti M, Pezone N, Pota A, Russo L, Sacco M, Scogna miglio B. Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis. Kidney Int 80: 112-118, 2011.
97. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 27: 2302-2309, 2007.
98. Schinke T, Amendt C, Trindl A, Poschke O, Miller-Esterl W, Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 271: 20789-20796, 1996.
99. Schoppet M, Hofbauer LC, Brinskelle-Schmal N, Varennes A, Goud-able J, Richard M, Hawa G, Chapurlat R, Szulc P. Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study. J Clin Endocrinol Metab 97: E575-E583, 2012.
100. Schurgers LJ, Barreto DV, Barreto FC, Liabeuf S, Renard C, Magdeleyns EJ, Vermeer C, Choukroun G, Massy ZA. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol 5: 568-575, 2010.
101. Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang H., Crouthamel MH, Chavkin NW, Rahman M, Wahl P, Amaral AP, Hamano T, Master SR, Nessel L, Chai B, Xie D, Kallem RR, Chen J, Lash JP, Kusek JW, Budoff MJ, Giachelli CM, Wolf M. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 83: 1159-1168, 2013.
102. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 109: 697-711, 2011.
103. Shanahan CM. Autophagy and matrix vesicles: new partners in vascular calcification. Kidney Int 83: 984-986, 2013.
104. Shobeiri N, Adams MA, Holden RM. Phosphate: an old bone molecule but new cardiovascular risk factor. Br J Clin Pharmacol 77: 39-54, 2014.
105. Shroff R. Phosphate is a vascular toxin. Pediatr Nephrol 28: 583-593, 2013.
106. Shroff R., McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield J, Rees L, Shanahan CM. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 118: 1748-1757, 2008.
107. Shroff R., McNair R, Skepper JN, Figg N, Schurgers LJ, Deanfield J, Rees L, Shanahan CM. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 21: 103-112, 2010.
108. Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2: 1241-1248, 2007.
109. Smith ER, Cai MM, McMahon LP, Pedagogos E, Toussaint ND, Brumby C, Holt SG. Serum fetuin-A concentration and fetuin-A-containing calciprotein particles in patients with chronic inflammatory disease and renal failure. Nephrology (Carlton) 18: 215-221, 2013.
110. Smith ER, Ford ML, Tomlinson LA, Bodenham E, McMahon LP, Farese S, Rajkumar C, Holt SG, Pasch A. Serum calcification propensity predicts all-cause mortality in predialysis CKD. J Am Soc Nephrol 25: 339-348, 2014.
111. Smith ER, Hanssen E, McMahon LP, Holt SG. Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage. PLoS ONE 8: e60904, 2013.
112. Son BK, Kozaki K, Iijima K, Eto M, Nakano T, Akishita M, Ouchi Y. Gas6/Axl-PI3K/Akt pathway plays a central role in the effect of statins on inorganic phosphate-induced calcification of vascular smooth muscle cells. Eur J Pharmacol 556: 1-8, 2007.
113. Sonikian M, Papachristou E, Goumenos DS. Optimal use of phosphate binders in chronic kidney disease. Expert Opin Pharmacother 14: 2521-2532, 2013.
114. Speer MY, Giachelli CM. Regulation of cardiovascular calcification. Cardiovasc Pathol 13: 63-70, 2004.
115. Speer MY, Li X, Hiremath PG, Giachelli CM. Runx2/Cbfa1, but not loss of myocardin, is required for smooth muscle cell lineage reprogram-ming toward osteochondrogenesis. J Cell Biochem 110: 935-947, 2010.
116. Spiro RG. Studies on fetuin, a glycoprotein of fetal serum. I. Isolation, chemical composition, and physiochemical properties. J Biol Chem 235: 2860-2869, 1960.
117. Sun Y, Byon CH, Yuan K, Chen J, Mao X, Heath JM, Javed A, Zhang K, Anderson PG, Chen Y. Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification. Circ Res 111: 543-552, 2012.
118. Takeda E, Taketani Y, Morita K, Miyamoto K. Sodium-dependent phosphate co-transporters. Int J Biochem Cell Biol 31: 377-381, 1999.
119. Tanimura A, McGregor DH, Anderson HC. Matrix vesicles in atherosclerotic calcification. Proc Soc Exp Biol Med 172: 173-177, 1983.
120. Tsukii K, Shima N, Mochizuki S, Yamaguchi K, Kinosaki M, Yano K, Shibata O, Udagawa N, Yasuda H, Suda T, Higashio K. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun 246: 337-341, 1998.
121. Tsuruta Y, Ohbayashi T, Fujii M, Myochin H, Mizutani R, Narita M, Maeda K. Change in coronary artery calcification score due to cinacalcet hydrochloride administration. Ther Apher Dial 12, Suppl 1: S34-S37, 2008.
122. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 23: 489-494, 2003.
123. Utsunomiya M. [Angiographic study of stenosis and calcification of coronary vessels in long-term dialysis patients: examination of risk factors for coronary calcification]. Nihon Jinzo Gakkai Shi 38: 155-163,1996.
124. Wen P, Cao H, Fang L, Ye H, Zhou Y, Jiang L, Su W, Xu H, He W, Dai C, Yang J. miR-125b/Ets1 axis regulates transdifferentiation and calcification of vascular smooth muscle cells in a high-phosphate environment. Exp Cell Res 322: 302-312, 2014.
125. Werner A, Dehmelt L, Nalbant P. Na+-dependent phosphate cotrans-porters: the NaPi protein families. J Exp Biol 201: 3135-3142, 1998.
126. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 66: 2293-2299, 2004.
127. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139: 1329-1337, 1998.